Article Per Year (5 Year)
p-Index From 2021 - 2026
1.922
P-Index
This Author published in this journals
All Journal Jurnal Respirologi Indonesia Jurnal Buana Farma Eduvest - Journal of Universal Studies PCJN Pharmaceutical and Clinical Journal of Nusantara Herbal Medicine Journal
Harahap, Daimah Wirdatus Sanaun
Unknown Affiliation
Aerospace Engineering Biochemistry, Genetics & Molecular Biology Chemistry Computer Science & IT Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Public Health Social Sciences

Published : 12 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 12 Documents
Search

 1   2 
EFEKTIVITAS DAN BIAYA SEFALOSPORIN PADA PASIEN SIROSIS HEPATIS DENGAN RISIKO SPONTANEOUS BACTERIAL PERITONITIS DI RUMAH SAKIT ROYAL PRIMA PADA TAHUN 2022-2025 Dakhi, Grace Kristin Sonayania; Harahap, Daimah Wirdatus Sanaun; Br Ginting, Astriani Natalia
Jurnal Buana Farma Vol 6 No 1 (2026): Jurnal Buana Farma
Publisher : Fakultas Farmasi Universitas Buana Perjuangan Karawang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36805/jbf.v6i1.1694

Abstract

Hepatic cirrhosis is a chronic liver disease often accompanied by serious complications, one of which is spontaneous bacterial peritonitis (SBP), which plays a significant role in increasing morbidity and mortality. Third-generation cephalosporin antibiotics, such as cefotaxime and ceftriaxone, are widely used as first-line therapy in patients with hepatic cirrhosis at risk of SBP. However, the increasing incidence of bacterial resistance and the high cost of treatment require an evaluation of the clinical effectiveness and cost-efficiency of the therapy provided. This study aims to assess the effectiveness and cost of using cephalosporin antibiotics in patients with hepatic cirrhosis at risk of SBP at Royal Prima Hospital Medan during the period 2022–2025. This study uses a pharmacoeconomic approach in the form of Cost-Effectiveness Analysis (CEA) to assess the cost-effectiveness of cephalosporins based on the relationship between treatment costs and patient clinical outcomes. Cost-effectiveness is assessed through the calculation of the Cost-Effectiveness Ratio (CER). The results show that the characteristics of patients are predominantly male and in the adult to elderly age group. This finding is in line with the epidemiological characteristics of liver cirrhosis which is more common in men, especially due to long-term risk factors such as chronic liver disease and alcohol consumption. The study shows that the analysis of the Cost-Effectiveness Ratio (CER) and Cost-Effectiveness Analysis (CEA) values has a positive and significant effect on total medical costs, which indicates that increasing costs per unit of clinical outcomes will have a direct impact on increasing total treatment costs.
EVALUASI PENGGUNAAN OBAT PADA PASIEN DISPEPSIA MENGGUNAKAN METODE ATC/DDD DI RUMAH SAKIT ROYAL PRIMA TAHUN 2022 Hutabarat, Rachel Epifanes; Harahap, Daimah Wirdatus Sanaun; Ginting, Astriani Natalia Br
Jurnal Buana Farma Vol 6 No 1 (2026): Jurnal Buana Farma
Publisher : Fakultas Farmasi Universitas Buana Perjuangan Karawang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36805/jbf.v6i1.1677

Abstract

Dyspepsia is a common non-communicable disease that requires pharmacotherapy management according to clinical guidelines. Evaluation of drug use can be conducted using the ATC/DDD (Anatomical Therapeutic Chemical/Defined Daily Dose) and DU90% (Drug Utilization 90%) methods to describe prescribing patterns in healthcare facilities. This study aimed to evaluate drug use in dyspepsia patients at Royal Prima Hospital Medan in 2022 using a retrospective descriptive design using medical records of 180 patients from January–December 2022. Drugs were classified based on the WHO 2023 ATC system and analyzed using DDD calculations and the DU90% method. The results showed that four drugs included in the DU90% segment were omeprazole (tablets and injections) and ranitidine (tablets and injections), with a total contribution of 90.4% of the total DDD. The pattern of drug use is dominated by proton pump inhibitors and H₂ receptor antagonists, which are the main therapies in the management of dyspepsia based on the 2022 National Consensus on the Management of Dyspepsia and Helicobacter pylori Infection, so that the distribution of drug use obtained in this study shows compliance with national therapy recommendations.
Co-Authors Alya, Cinta Bangar, Roy Indrianto Br Ginting, Astriani Natalia Br Sembiring, Novitaria Dakhi, Grace Kristin Sonayania Diah Handayani Ginting, Astriani Natalia Br Hutabarat, Rachel Epifanes Iksen, Iksen Kasta Gurning Lumban Gaol, Irma Yohana Mahzura, Siti Nasution, Nursaima Putri Ningsih, Wulan Seppia Retnosari Andrajati Santi Purna Sari Sihotang, Nurhanifah Syahputra, Hariyadi Dharmawan Vera Estefania Kaban